Non-Hodgkin's Lymphoma, Phase III
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Volunteers
Health Professionals
What is the purpose of this trial?
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- D. Barry Boyd, MD, MS
- Elan Gorshein, DO, JD, MPH
- Emily Kopas, APRN, OCN
- Ethan Kohn, PA
- Francesca Montanari, MD
- Iris Isufi, MD
- Jadwiga Kretowicz, APRN
- Justine Boulanger-Parzych, APRN
- Larisa Fleysher, APRN
- M. Sung Lee, MD
- Natalia Neparidze, MD
- Sabrina Browning, MD
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Stuart Seropian, MD
- Tarsheen Sethi, MD, MSc
- Terri Parker, MD
- Last Updated05/17/2026
- Study IRB#2000038321